179 related articles for article (PubMed ID: 35100723)
1. Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
Degtyarev E; Zhang Y; Sen K; Lebwohl D; Akacha M; Hampson LV; Bornkamp B; Maniero A; Bretz F; Zuber E
JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100723
[TBL] [Abstract][Full Text] [Related]
2. [What Is an Estimand?-The Most Important Clinical Question in Oncology Trials].
Hamasaki T; Bretz F
Gan To Kagaku Ryoho; 2022 Apr; 49(4):381-388. PubMed ID: 35444118
[TBL] [Abstract][Full Text] [Related]
3. Estimands in hematologic oncology trials.
Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
[TBL] [Abstract][Full Text] [Related]
4. Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
Casey M; Degtyarev E; Lechuga MJ; Aimone P; Ravaud A; Motzer RJ; Liu F; Stalbovskaya V; Tang R; Butler E; Sailer O; Halabi S; George D
Pharm Stat; 2021 Mar; 20(2):324-334. PubMed ID: 33155417
[TBL] [Abstract][Full Text] [Related]
5. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
6. Application of the Estimand Framework to Anesthesia Trials.
De Silva AP; Leslie K; Braat S; Grobler AC
Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
[TBL] [Abstract][Full Text] [Related]
7. Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
Englert S; Mercier F; Pilling EA; Homer V; Habermehl C; Zimmermann S; Kan-Dobrosky N
Pharm Stat; 2023; 22(5):921-937. PubMed ID: 37403434
[TBL] [Abstract][Full Text] [Related]
8. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
9. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
10. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
[TBL] [Abstract][Full Text] [Related]
11. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
[TBL] [Abstract][Full Text] [Related]
12. Estimands and Complex Innovative Designs.
Collignon O; Schiel A; Burman CF; Rufibach K; Posch M; Bretz F
Clin Pharmacol Ther; 2022 Dec; 112(6):1183-1190. PubMed ID: 35253205
[TBL] [Abstract][Full Text] [Related]
13. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
[TBL] [Abstract][Full Text] [Related]
14. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework.
Grobler AC; Lee KJ; Wong A; Currow DC; Braat S
J Pain Symptom Manage; 2022 Apr; 63(4):e431-e439. PubMed ID: 34954068
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework.
Degtyarev E; Rufibach K; Shentu Y; Yung G; Casey M; Englert S; Liu F; Liu Y; Sailer O; Siegel J; Sun S; Tang R; Zhou J;
Stat Biopharm Res; 2020 Jul; 12(4):427-437. PubMed ID: 34191975
[No Abstract] [Full Text] [Related]
16. Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance.
Siegel JM; Weber HJ; Englert S; Liu F; Casey M;
Pharm Stat; 2024 Mar; ():. PubMed ID: 38553421
[TBL] [Abstract][Full Text] [Related]
17. Understanding estimands.
Gogtay NJ; Ranganathan P; Aggarwal R
Perspect Clin Res; 2021; 12(2):106-112. PubMed ID: 34012908
[TBL] [Abstract][Full Text] [Related]
18. Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
Bissonnette R; Eichenfield LF; Simpson E; Thaçi D; Kabashima K; Thyssen JP; Guttman-Yassky E; Nunes FP; Gamalo M; Ahmad F; Kuligowski M; Sun K; Pipper C; Christensen AW; D'Angelo P; Milutinovic M; Guettner A; Silverberg JI
J Eur Acad Dermatol Venereol; 2023 May; 37(5):976-983. PubMed ID: 36652273
[TBL] [Abstract][Full Text] [Related]
19. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
20. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
Mehrotra DV
Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
